Literature DB >> 8472394

Reactive oxygen metabolites, neutrophils, and the pathogenesis of ischemic-tissue/reperfusion.

R J Korthuis1, D N Granger.   

Abstract

Considerable research effort has been directed at elucidating the mechanisms underlying the pathophysiologic alterations associated with reperfusion (reoxygenation) of ischemic (hypoxic) tissues. As a consequence of this intensive effort, a large body of evidence has accumulated, implicating a role for reactive oxygen metabolites and activated granulocytes in the genesis of postischemic cellular dysfunction. Figure 1 summarizes a hypothesis that has been proposed to explain the interaction of xanthine oxidase-derived oxidants, granulocyte infiltration, and the microvascular and parenchymal cell dysfunction that occurs in postischemic tissues. According to this scheme, xanthine oxidase-derived oxidants, produced at reperfusion, initiate the formation and release of proinflammatory agents, which subsequently attract and activate granulocytes. The activated neutrophils adhere to the microvascular endothelium, extravasate, and release cytotoxic oxidants and proteases, which contribute to tissue dysfunction. The aim of this review is to summarize the evidence that we and others have accumulated in support of this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8472394     DOI: 10.1002/clc.4960161307

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  16 in total

1.  Pathobiology and Clinical Impact of Reperfusion Injury.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1997       Impact factor: 2.300

Review 2.  Ischemia-reperfusion damage.

Authors:  Omer E Yapca; Bunyamin Borekci; Halis Suleyman
Journal:  Eurasian J Med       Date:  2013-06

3.  Neuroprotective role of Nrf2 for retinal ganglion cells in ischemia-reperfusion.

Authors:  Zhenhua Xu; Hongkwan Cho; Matthew J Hartsock; Katherine L Mitchell; Junsong Gong; Lijuan Wu; Yanhong Wei; Shuang Wang; Rajesh K Thimmulappa; Michael B Sporn; Shyam Biswal; Derek S Welsbie; Elia J Duh
Journal:  J Neurochem       Date:  2015-03-04       Impact factor: 5.372

4.  Pentoxifylline attenuates ischemia/reperfusion injury to the small intestine in the rat.

Authors:  R Udassin; A Vromen; D Seror; Y Haskel
Journal:  Pediatr Surg Int       Date:  2013-09-21       Impact factor: 1.827

5.  Human epicardial cell-conditioned medium contains HGF/IgG complexes that phosphorylate RYK and protect against vascular injury.

Authors:  Krithika S Rao; Alexander Aronshtam; Keara L McElory-Yaggy; Benjamin Bakondi; Peter VanBuren; Burton E Sobel; Jeffrey L Spees
Journal:  Cardiovasc Res       Date:  2015-05-29       Impact factor: 10.787

6.  Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury.

Authors:  Yanhong Wei; Junsong Gong; Takeshi Yoshida; Charles G Eberhart; Zhenhua Xu; Ponvijay Kombairaju; Michael B Sporn; James T Handa; Elia J Duh
Journal:  Free Radic Biol Med       Date:  2011-04-19       Impact factor: 7.376

7.  Preservation injury and acute rejection of rat intestinal grafts: protection afforded by pyruvate.

Authors:  L Cicalese; V Subbotin; C Rastellini; R T Stanko; A S Rao; J J Fung
Journal:  J Gastrointest Surg       Date:  1999 Sep-Oct       Impact factor: 3.452

8.  Pathobiology and Clinical Impact of Reperfusion Injury.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

Review 9.  Mammalian molybdo-flavoenzymes, an expanding family of proteins: structure, genetics, regulation, function and pathophysiology.

Authors:  Enrico Garattini; Ralf Mendel; Maria João Romão; Richard Wright; Mineko Terao
Journal:  Biochem J       Date:  2003-05-15       Impact factor: 3.857

10.  Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion.

Authors:  D D Koo; K I Welsh; J A Roake; P J Morris; S V Fuggle
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.